Wutah pendapatan YoY sajrone 12 wulan kepungkur: OmniAb, Inc. (OABI)

The YoY revenue growth trend for TTM reflects the dynamics of OmniAb, Inc. (OABI), which develops antibodies through strategic alliances with pharmaceutical behemoths. Financial results are based on partners reaching clinical development milestones. While demand is limited by biotech budgets, the absence of debt offsets any cash flow gaps. The latest value is recorded as 90.40, providing a real-time assessment of the business scale.
OmniAb (OABI) - rincian metrik lan laporan keuangan

This indicator measures the percentage change in revenue over a rolling twelve-month period, allowing investors to filter out short-term volatility and assess the actual pace of business scaling. An analysis of the LTM year-over-year sales dynamics confirms the effectiveness of the OmniAb, Inc. transgenic animal platform, where revenue growth is driven by high-margin royalties from numerous partnerships with pharmaceutical behemoths.